Fig 1: IGF2BP1 binds and recognizes the METTL3-mediated m6A modification on ABL, maintaining ABL stability. A) The ABL levels in BGC823 cells with IGF2BP1 deficiency were determined by qRT-PCR. B) Western blot detection of IGF2BP1 pulled down by in vitro-transcribed biotinylated ABL from BGC-823 cell lysates. Sen., sense transcript; as., antisense transcript. C) The interaction of ABL with IGF2BP1 in BGC823 cells was examined by a RIP-qPCR assay. D) Confocal images showing colocalization of ABL (red) and IGF2BP1 (green) in BGC823 cells (scale bars = 5 µm). E) Graphic illustration of IGF2BP1 deletion mutants. F) In vitro RNA protein binding assay showing the interaction of biotinylated ABL with HA-tagged IGF2BP1 proteins, including the WT protein and RRM, KH1/2, or KH3/4 deletion mutants. G) In vitro RNA pull-down coupled with a dot blot assay using the indicated RNA transcripts and recombinant IGF2BP1 proteins. Bottom panel: Annotation of each dot. H) In vitro-transcribed antisense, sense, sense with deletion of nt 121–180 (binding region for IGF2BP1) or sense with deletion of nt 481–540 (binding region for APAF1) ABL transcripts were incubated with recombinant His-IGF2BP1 proteins for an in vitro streptavidin RNA pull-down assay, followed by Western blot detection using an anti-His antibody. I) Graphic illustration of the “CACA” motif in ABL for IGF2BP1 binding and the “GGAC” motif, including the m6A modification site for IGF2BP1 recognition. J) Schematic presentation of the construction of the luciferase reporter containing ABL-WT or ABL-Mut region. K) Relative luciferase activity of the ABL-WT or ABL-Mut luciferase reporter in BGC823 cells with IGF2BP1 overexpression and corresponding control cells was detected. L) The calculated protein–RNA interaction model between IGF2BP1 and ABL (nt 121–180). M,N) The ABL levels in GC cells with wild-type or catalytic mutant (Mut) METTL3 overexpression and METTL3-deficient were detected by qRT-PCR. O) MeRIP-qPCR analysis was used to demonstrate METTL3-mediated m6A modifications on ABL. The m6A modification of ABL was increased upon upregulation of wide type METTL3 while no significant change upon of Mut METTL3. P) RIP-qPCR analysis was used to demonstrate that IGF2BP1 could enrich more ABL upon overexpression of METTL3. Q) The levels of ABL expression in METTL3-overexpressing and corresponding control GC cells treated with actinomycin D (2 µg mL-1) at the indicated time points were detected by qRT-PCR. R) The levels of ABL expression in IGF2BP1-deficient and corresponding control GC cells treated with actinomycin D (2 µg mL-1) at the indicated time points were detected by qRT-PCR. S) Representative images of the cell colony formation abilities of METTL3-overexpressing BGC823 cells transfected with ABL-specific siRNAs or corresponding controls and treated with DDP at the indicated doses for 24 h. T) Quantification of the colony formation assay results in (S). U) Immunoprecipitation (IP) and Western blotting were used to detect the interaction between APAF1 and Cyt c in IGF2BP1 or METTL3 deficient BGC823 cells after DDP treatment at 1 µg mL-1 for 24 h. The data were analyzed by a two-tailed unpaired Student's t-test (A, C, K, M–R, and T). The data are represented as the means ± SEM of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001, NS, no significance.
Fig 2: ABL antagonizes GC cell apoptosis by competitively blocking the binding of APAF1 with Cyt c. A) Western blotting was applied to determine the expression of the indicated proteins in ABL-overexpressing BGC823 cells after DDP treatment at 0 or 1 µg mL-1 for 24 h. B) Immunoprecipitation (IP) and Western blotting were used to detect the interaction between APAF1 and Cyt c in ABL-overexpressing BGC823 cells after DDP treatment at 0 or 1 µg mL-1 for 24 h. C) Confocal images showing colocalization of APAF1 (green) and Cyt c (red) in ABL-overexpressing BGC823 cells after DDP treatment at 1 µg mL-1 for 24 h (scale bars = 25 µm, left panel). Right panel: the images were subject to Z-axis profile analysis. D) Caspase-9 activity was detected in ABL-overexpressing BGC823 cells and corresponding control cells after DDP treatment at 1 µg mL-1 for 24 h. E) Docking analysis of the protein–protein or protein–RNA interaction model between APAF1-Cyt c and APAF1-ABL (nt 481–540), respectively. F) His-tagged WD1/WD2 domain of APAF1 bound to Ni-NTA beads was incubated with or without increasing amounts of 1 or 2 µg ABL sense, anti-sense, or mutant sense (?APAF1) and purified GST-Cyt c. Bead-bound proteins and the input were analyzed by western blot and coomassie blue staining. G) An annexin-V-FITC/PI assay was used to detect apoptotic ABL-overexpressing BGC823 cells after DDP treatment at 0 or 1 µg mL-1 for 24 h. H) Quantification of the apoptotic cells in (G). I) A TUNEL assay was used to detect apoptotic ABL-overexpressing and corresponding control BGC823 cells after DDP treatment at 0 or 1 µg mL-1 for 24 h. J) Quantification of the apoptotic cells in (I). The data were analyzed by a two-tailed unpaired Student's t-test (D, H, and J). The data are represented as the means ± SEM of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001, NS, no significance.
Fig 3: ABL directly binds to APAF1. A) Localization of ABL in BGC823 cells detected by RNA-FISH. U6 and 18S rRNA were used as positive controls for the nuclear and cytoplasmic fractions, respectively. B) Coomassie brilliant blue staining of proteins pulled down by biotinylated ABL. Sen., sense transcript; as., antisense transcript. C) Western blot detection of APAF1 pulled down by in vitro-transcribed biotinylated ABL from BGC-823 cell lysates. GAPDH was used as a negative control. D) The interaction of ABL with APAF1 in BGC823 cells was shown by RIP-qPCR detection of the ABL pulled down by an anti-APAF1 antibody. E) Confocal images showing colocalization of ABL (red) and APAF1 (green) in BGC823 cells (scale bars = 5 µm, left panel). Right panel: the images were subject to Z-axis profile analysis. F) In vitro RNA pull-down coupled with a dot blot assay using the indicated RNA transcripts and recombinant APAF1 proteins. Bottom panel: Annotation of each dot. G) In vitro-transcribed antisense, sense, or sense with deletion of nt 481–540 (binding region for APAF1) ABL transcripts were incubated with recombinant histidine (His)-tagged APAF1 proteins for an in vitro streptavidin RNA pull-down assay, followed by Western blot detection using an anti-His antibody. H) Graphic illustration of APAF1 deletion mutants. I) In vitro RNA protein binding assay showing the interaction of biotinylated ABL with Flag-tagged APAF1 proteins, including the WT protein and CARD, NB-ARC, WD1, WD2, or WD1/WD2 deletion mutants. J) Docking analysis of the protein-RNA interaction model between APAF1 and ABL (nt 481–540). K) Genomic distribution of the APAF1 binding peaks from LACE-seq reads. L) The meta profile of APAF1-RNA interacting sites. TSS: transcription start site; TTS: transcription termination site. M) Enriched sequence among APAF1-RNA crosslinking sites by the Multiple Em for Motif Elicitation (MEME) tool. N) RIP-qPCR analysis was used to detect whether APAF1 could enrich the mRNAs or lncRNAs identified in LACE-seq. The data were analyzed by a two-tailed unpaired Student's t-test (D and N). The data are represented as the means ± SEM of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001, NS, no significance.
Supplier Page from Abcam for Recombinant Human APAF1 protein (Tagged)